Pharmaceutical intermediates
Dasatinib Hydrate Intermediates
2 pharmaceutical intermediates for Dasatinib Hydrate. Indication: Acute lymphoblastic leukemia; Chronic myeloid leukemia.
About Dasatinib Hydrate
- Originator
- Bristol Myers Squibb
- Indication
- Acute lymphoblastic leukemia; Chronic myeloid leukemia
- Approved Date
- 06/28/2006
- DS/DP
- 02/04/2025
Available intermediates
2 intermediates currently listed for Dasatinib Hydrate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (E)-N-(2-Chloro-6-methylphenyl)-3-ethoxyacrylamide | 863127-76-8 | / | / |
| 2-Amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide | 302964-24-5 | / | / |
Building toward Dasatinib Hydrate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →